Psoriasis, Psoriatic Arthritis
Conditions
Keywords
psoriasis, psoriatic arthritis, screening tool
Brief summary
This study evaluates a new screening tool for arthritis in psoriasis and compares its reliability with well-known screening tool (TOPAS 2).
Detailed description
Early diagnosis and treatment of PsA may prevent destruction in joints.Our aim is to create a simple and user friendly screening tool that can be used by dermatologists in out patient clinics. A question pool will be created from a review of the literature and expert opinions from a physicians experienced in rheumatology and dermatologists .Psoriasis patients will answer these newly created questions. All patients will be examined by dermatology and also physical therapy and rehabilitation-rheumatology experts. The diagnosis of psoriatic arthritis (PsA) will be made by CASPAR (Classification criteria for psoriatic arthritis) criteria and ASAS (Assessment of Spondyloarthritis International Society) criteria for spondyloarthritis. Synchronously patients will be asked for to reply Turkish version of well known questionary named TOPAS 2. According to the results of collected data, statistically best matched questions will be selected for Turkish population. Also, the reliability of TUPAST (Turkish PsA Screening Tool) and TOPAS 2 (Toronto Psoriatic Arthritis Screen II) will be compared statistically.
Interventions
DIAGNOSTIC_TESTQuestionary
All patients will answer two different questionary (TUPAST, TOPAS 2)
Sponsors
Bezmialem Vakif University
Study design
Observational model
COHORT
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Psoriasis confirmed by dermatologist
Exclusion criteria
* Unable to consent and understand * Known other rheumatological disease
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Creation of new tool (TUPAST: Turkish psoriatic arthritis screening tool) for detecting psoriatic arthritis among psoriasis patients | six months, throughout the study | Questions which related with psoriatic arthritis will be selected statistically. Factor analysis will be performed to select the questions to construct the questionnaire. ROC (receiver operating characteristic) will be used to pick the best cut point for tool. Then, sensitivity and specificity of new tool to detect psoriatic arthritis among psoriasis patients will be calculated. |
| Correlation between TOPAS 2 score and probability of psoriatic arthritis in psoriasis patients | six months, throughout the study | TOPAS 2 (Toronto Psoriatic Arthritis Screen II ) is a questionnaire for detecting psoriatic arthritis which has 95.8% sensitivity and 98% specificity in Turkish population. All patients will answer TOPAS 2 questions and all patients will be examined by dermatology and also physical therapy and rehabilitation-rheumatology experts.The diagnosis of psoriatic arthritis (PsA) will be made by CASPAR (Classification criteria for psoriatic arthritis) criteria and ASAS (Assessment of Spondyloarthritis International Society) criteria for spondyloarthritis.Then, sensitivity and specificity of TOPAS 2 will be calculated in our group and the correlation between psoriatic arthritis and screening tool results will be seen. |
| Comparison of the reliability of the TUPAST and TOPAS 2 | six months, throughout the study | All patients will answer TUPAST and TOPAS 2 at the same time. According to statistical results, reliability of this two tool will be compared. |
| Correlation between TUPAST score and probability of psoriatic arthritis in psoriasis patients | six months, throughout the study | All patients will answer TUPAST questions and all patients will be examined by dermatology and also physical therapy and rehabilitation-rheumatology experts.The diagnosis of psoriatic arthritis (PsA) will be made by CASPAR (Classification criteria for psoriatic arthritis) criteria and ASAS (Assessment of Spondyloarthritis International Society) criteria for spondyloarthritis. Then, sensitivity and specificity of TOPAS 2 will be calculated in our group and the correlation between psoriatic arthritis and screening tool results will be seen. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Demographic characteristics demographic characteristics demographic characteristics | six months | Demographic characteristics of patients will be compared (especially between PsA and non PsA group) |
Countries
Turkey (Türkiye)
Outcome results
None listed